ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

NCI To Offer Compromise On Including “Chop-Like Elements” In CCOP, Agrees Consortia “Appropriate”

May 14, 1982

Small Business Technology Transfer Program Solicitation

June 23, 1995

Zaltrap Receives Positive Opinion For European Market From CHMP

November 30, 2012

INSPIRE Enrollment Stopped; Thromboembolism Risk Cited

February 25, 2011

Prospects Fading for Funding More CCOPsIn FY ’83; Return to Groups Of Money From Satellites Going To New Programs

July 29, 1983

New Jersey Center Takes Slice of DOE Budget for Cancer

January 8, 1988